ClinicalTrials.gg
CompletedNCT06393452Updated Oct 21, 2026Results posted

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

A Phase 2 interventional study of PP405 0.05% Topical Gel and Topical Vehicle Gel in Androgenetic Alopecia, sponsored by Pelage Pharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Pelage Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Updated Oct 21, 2026Posted results revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
55th of 203
78 · median 40
Started
2024
with 19 others
Phase 2
47 of 216
6 open now
Registered
172nd of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 55th largest by enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2024, is one of 47 in phase 2, and was the 172nd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.

Read the detailed description

Safety, Pharmacokinetics, and Efficacy Study of PP405 in subjects with Androgenetic Alopecia.

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 55 years.
  2. Able and willing to provide written .
  3. Males must have an AGA modified Norwood-Hamilton Classification score of Type III vertex, Type IV or Type V. Females must have a Savin classification score of I-2, I-3 or I-4.
  4. Agree to comply with protocol procedures

Exclusion criteria

Exclusion Criteria:

  1. Concomitant diagnosis of non-AGA forms of alopecia.
  2. Use of other hair loss treatments within periods specified in protocol.
  3. Use of excluded medications as specified in protocol.
  4. Diagnosis of other medical conditions as specified in protocol.
  5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (actual)

Study arms

  • Active comparator
    PP405 0.05% Topical Gel

    PP405 0.05% Topical Gel applied once daily for 28 days.

    Drug: PP405 0.05% Topical Gel

  • Placebo comparator
    Topical Vehicle Gel, then PP405 0.05% Topical Gel

    Topical Placebo Gel applied once daily for 28 days. Following the initial treatment and follow-up period through day 84, eligible subjects crossed over to apply PP405 0.05% topical gel for 84 days in an open-labeled extension.

    Drug: PP405 0.05% Topical Gel · Drug: Topical Vehicle Gel

Interventions

  • Medicated topical gel containing PP405 0.05%, applied once daily to the scalp

    Also known as: PP405 0.05%

  • DrugTopical Vehicle Gel

    Vehicle = placebo topical gel

    Also known as: Topical Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Adverse Events

    An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase

    Time frame: Baseline to Day 84 of the randomized portion of the study

  2. Percentage of Subjects With Adverse Events

    An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  3. Change in Local Dermal Tolerability as Assessed by Subject and Investigator

    Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema

    Time frame: Post-dose at day 28 of the randomized portion of the study

  4. Change in Local Dermal Tolerability as Assessed by Subject and Investigator

    Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema

    Time frame: Post-dose at day 84 of the open label extension portion of the study

  5. Change From Baseline in Blood Pressure

    Change from baseline in blood pressure in the safety analysis population (day 84 minus baseline)

    Time frame: Baseline to Day 84 of the randomized portion of the study

  6. Change From Baseline in Pulse Rate

    Change from baseline in pulse rate in the safety analysis population (day 84 minus baseline)

    Time frame: Baseline to Day 84 of the randomized portion of the study

  7. Change From Baseline in Temperature

    Change from baseline in temperature in the safety analysis population (day 84 minus baseline)

    Time frame: Baseline to Day 84 of the randomized portion of the study

  8. Change From Baseline in Respiratory Rate

    Change from baseline in respiratory rate in the safety analysis population (day 84 minus baseline)

    Time frame: Baseline to Day 84 of the randomized portion of the study

  9. Change From Baseline in Weight

    Change from baseline in weight in the safety analysis population (day 84 minus baseline)

    Time frame: Baseline to Day 84 of the randomized portion of the study

  10. Change From Baseline in Blood Pressure

    Change from baseline in blood pressure in the safety analysis population (open label extension day 84 minus open label extension baseline)

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  11. Change From Baseline in Pulse Rate

    Change from baseline in pulse rate in the safety analysis population (open label extension day 84 minus open label extension baseline)

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  12. Change From Baseline in Temperature

    Change from baseline in temperature in the safety analysis population (open label extension day 84 minus open label extension baseline)

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  13. Change From Baseline in Respiratory Rate

    Change from baseline in respiratory rate in the safety analysis population (open label extension day 84 minus open label extension baseline)

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  14. Change From Baseline in Weight

    Change from baseline in weight in the safety analysis population (open label extension day 84 minus open label extension baseline)

    Time frame: Baseline to Day 84 of the open label extension portion of the study

  15. Change From Baseline in Mean Electrocardiogram Heart Rate

    Electrocardiogram mean heart rate was compared to baseline (day 28 minus baseline)

    Time frame: Baseline to day 28 of the randomized portion of the study

  16. Change From Baseline in Electrocardiogram (ECG) Results

    Electrocardiograms results were compared to baseline (day 28 minus baseline)

    Time frame: Baseline to day 28 of the randomized portion of the study

  17. Change From Baseline in Mean Electrocardiogram Heart Rate

    Mean Electrocardiogram Heart Rate was compared to baseline of the open label extension study (day 84 minus baseline)

    Time frame: Baseline to day 84 of the open label extension portion of the study

  18. Change From Baseline in Electrocardiograms (ECGs)

    Electrocardiograms results were compared to baseline of the open label extension study (day 84 minus baseline)

    Time frame: Baseline to day 84 of the open label extension portion of the study

  19. Abnormal Laboratory Values

    Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)

    Time frame: Day 28 post baseline in the randomized portion of the study

  20. Abnormal Laboratory Values

    Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)

    Time frame: Day 84 post baseline in the open label extension portion of the study

Secondary outcomes

  1. Pharmacokinetics of PP405

    To assess the concentration of PP405 in plasma

    Time frame: Baseline to Day 28 of the randomized portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 14, and day 28

  2. Pharmacokinetics of PP405

    To assess the concentration of PP405 in plasma

    Time frame: Baseline to Day 84 of the open label extension portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 28, day 56, and day 84

07

Results

Posted Sep 22, 2026

Participant flow

Randomized Controlled Trial
Participant flow — Randomized Controlled Trial
MilestonePP405 0.05% Topical Gel Randomized Control Trial (28 Days of Treatment With Follow up to 84 Days)Topical Vehicle Gel (Randomized), Then PP405 0.05% Topical Gel (Open Label Extension)
Started5127
Completed4925
Not completed22
Open Label Extension
Participant flow — Open Label Extension
MilestonePP405 0.05% Topical Gel Randomized Control Trial (28 Days of Treatment With Follow up to 84 Days)Topical Vehicle Gel (Randomized), Then PP405 0.05% Topical Gel (Open Label Extension)
Started020
Completed017
Not completed03

Outcome measures

PrimaryPercentage of Subjects With Adverse Events

An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Count of participants · Participants
Percentage of Subjects With Adverse Events
ParticipantsPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
At least one adverse event2210
At least one treatment-emergent adverse event2210
At least one serious treatment-emergent adverse event01
PrimaryPercentage of Subjects With Adverse Events

An adverse event that was not present when the active phase of the study began and was not a chronic condition that was part of the subject's medical history; or, it was present at the start of the active phase of the study or as part of the subject's medical history, but the severity or frequency increased during the active phase

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Count of participants · Participants
Percentage of Subjects With Adverse Events
ParticipantsPP405 0.05% Topical Gel (Open Label Extension Period)
At least one adverse event8
At least one treatment-emergent adverse event8
At least one serious treatment-emergent adverse event0
PrimaryChange in Local Dermal Tolerability as Assessed by Subject and Investigator

Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema

Time frame:
Post-dose at day 28 of the randomized portion of the study
Reported as:
Count of participants · Participants
Change in Local Dermal Tolerability as Assessed by Subject and Investigator
ParticipantsPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Edema-investigator assessment — 0-None5126
Edema-investigator assessment — 1-Mild00
Edema-investigator assessment — 2-Moderate00
Edema-investigator assessment — 3-Severe00
Erythema-investigator assessment — 0-None5025
Erythema-investigator assessment — 1-Mild11
Erythema-investigator assessment — 2-Moderate00
Erythema-investigator assessment — 3-Severe00
Dryness-investigator assessment — 0-None5126
Dryness-investigator assessment — 1-Mild00
Dryness-investigator assessment — 2-Moderate00
Dryness-investigator assessment — 3-Severe00
Scaling-investigator assessment — 0-None5126
Scaling-investigator assessment — 1-Mild00
Scaling-investigator assessment — 2-Moderate00
Scaling-investigator assessment — 3-Severe00
Burning/stinging-subject assessment — 0-None5125
Burning/stinging-subject assessment — 1-Mild01
Burning/stinging-subject assessment — 2-Moderate00
Burning/stinging-subject assessment — 3-Severe00
Pruritis-subject assessment — 0-None5125
Pruritis-subject assessment — 1-Mild01
Pruritis-subject assessment — 2-Moderate00
Pruritis-subject assessment — 3-Severe00
PrimaryChange in Local Dermal Tolerability as Assessed by Subject and Investigator

Local skin reaction treatment emergent adverse events such as burning, pruritis, erythema

Time frame:
Post-dose at day 84 of the open label extension portion of the study
Reported as:
Count of participants · Participants
Change in Local Dermal Tolerability as Assessed by Subject and Investigator
ParticipantsPP405 0.05% Topical Gel (Open Label Extension Period)
Edema-investigator assessment — 0-None16
Edema-investigator assessment — 1-Mild0
Edema-investigator assessment — 2-Moderate0
Edema-investigator assessment — 3-Severe0
Erythema-investigator assessment — 0-None15
Erythema-investigator assessment — 1-Mild1
Erythema-investigator assessment — 2-Moderate0
Erythema-investigator assessment — 3-Severe0
Dryness-investigator assessment — 0-None16
Dryness-investigator assessment — 1-Mild0
Dryness-investigator assessment — 2-Moderate0
Dryness-investigator assessment — 3-Severe0
Scaling-investigator assessment — 0-None16
Scaling-investigator assessment — 1-Mild0
Scaling-investigator assessment — 2-Moderate0
Scaling-investigator assessment — 3-Severe0
Burning/stinging-subject assessment — 0-None16
Burning/stinging-subject assessment — 1-Mild0
Burning/stinging-subject assessment — 2-Moderate0
Burning/stinging-subject assessment — 3-Severe0
Pruritis-subject assessment — 0-None16
Pruritis-subject assessment — 1-Mild0
Pruritis-subject assessment — 2-Moderate0
Pruritis-subject assessment — 3-Severe0
PrimaryChange From Baseline in Blood Pressure

Change from baseline in blood pressure in the safety analysis population (day 84 minus baseline)

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure
millimeters of mercury (mmHg)PP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Systolic blood pressure-0.6 ± 12.47-4.2 ± 12.02
Diastolic blood pressure0.7 ± 10.171.1 ± 8.71
PrimaryChange From Baseline in Pulse Rate

Change from baseline in pulse rate in the safety analysis population (day 84 minus baseline)

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Mean · beats per min
Change From Baseline in Pulse Rate
beats per minPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Change From Baseline in Pulse Rate2.3 ± 9.89-2.3 ± 8.73
PrimaryChange From Baseline in Temperature

Change from baseline in temperature in the safety analysis population (day 84 minus baseline)

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Mean · degrees celcius
Change From Baseline in Temperature
degrees celciusPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Change From Baseline in Temperature0.110 ± 0.30840.000 ± 0.2931
PrimaryChange From Baseline in Respiratory Rate

Change from baseline in respiratory rate in the safety analysis population (day 84 minus baseline)

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Mean · breaths per minute
Change From Baseline in Respiratory Rate
breaths per minutePP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Change From Baseline in Respiratory Rate0.0 ± 1.86-0.1 ± 1.38
PrimaryChange From Baseline in Weight

Change from baseline in weight in the safety analysis population (day 84 minus baseline)

Time frame:
Baseline to Day 84 of the randomized portion of the study
Reported as:
Mean · kilograms
Change From Baseline in Weight
kilogramsPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Change From Baseline in Weight0.118 ± 1.99640.845 ± 2.1910
PrimaryChange From Baseline in Blood Pressure

Change from baseline in blood pressure in the safety analysis population (open label extension day 84 minus open label extension baseline)

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Blood Pressure
millimeters of mercury (mmHg)PP405 0.05% Topical Gel (Open Label Extension Period)
Systolic blood pressure-4.4 ± 10.91
Diastolic blood pressure-2.4 ± 5.91
PrimaryChange From Baseline in Pulse Rate

Change from baseline in pulse rate in the safety analysis population (open label extension day 84 minus open label extension baseline)

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate
beats per minutePP405 0.05% Topical Gel (Open Label Extension Period)
Change From Baseline in Pulse Rate1.4 ± 8.36
PrimaryChange From Baseline in Temperature

Change from baseline in temperature in the safety analysis population (open label extension day 84 minus open label extension baseline)

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Mean · degrees celcius
Change From Baseline in Temperature
degrees celciusPP405 0.05% Topical Gel (Open Label Extension Period)
Change From Baseline in Temperature0.017 ± 0.2787
PrimaryChange From Baseline in Respiratory Rate

Change from baseline in respiratory rate in the safety analysis population (open label extension day 84 minus open label extension baseline)

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Mean · breaths per minute
Change From Baseline in Respiratory Rate
breaths per minutePP405 0.05% Topical Gel (Open Label Extension Period)
Change From Baseline in Respiratory Rate0.1 ± 0.85
PrimaryChange From Baseline in Weight

Change from baseline in weight in the safety analysis population (open label extension day 84 minus open label extension baseline)

Time frame:
Baseline to Day 84 of the open label extension portion of the study
Reported as:
Mean · kilograms
Change From Baseline in Weight
kilogramsPP405 0.05% Topical Gel (Open Label Extension Period)
Change From Baseline in Weight-0.592 ± 3.2339
PrimaryChange From Baseline in Mean Electrocardiogram Heart Rate

Electrocardiogram mean heart rate was compared to baseline (day 28 minus baseline)

Time frame:
Baseline to day 28 of the randomized portion of the study
Reported as:
Mean · beats per minute
Change From Baseline in Mean Electrocardiogram Heart Rate
beats per minutePP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Change From Baseline in Mean Electrocardiogram Heart Rate0.6 ± 9.971.8 ± 9.06
PrimaryChange From Baseline in Electrocardiogram (ECG) Results

Electrocardiograms results were compared to baseline (day 28 minus baseline)

Time frame:
Baseline to day 28 of the randomized portion of the study
Reported as:
Mean · milliseconds (ms)
Change From Baseline in Electrocardiogram (ECG) Results
milliseconds (ms)PP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
PR Interval, Aggregate0.4 ± 11.873.8 ± 14.85
QRS Duration, Aggregate-0.6 ± 7.881.2 ± 5.57
QT Interval, Aggregate-0.9 ± 21.24-0.5 ± 21.90
QTcB Interval, Aggregate1.3 ± 23.644.6 ± 20.41
QTcF Interval, Aggregate0.5 ± 18.862.8 ± 17.58
RR Interval, Aggregate-9.7 ± 125.56-23.3 ± 123.29
PrimaryChange From Baseline in Mean Electrocardiogram Heart Rate

Mean Electrocardiogram Heart Rate was compared to baseline of the open label extension study (day 84 minus baseline)

Time frame:
Baseline to day 84 of the open label extension portion of the study
Reported as:
Mean · beats per minute
Change From Baseline in Mean Electrocardiogram Heart Rate
beats per minutePP405 0.05% Topical Gel (Open Label Extension Period)
Change From Baseline in Mean Electrocardiogram Heart Rate0.7 ± 11.06
PrimaryChange From Baseline in Electrocardiograms (ECGs)

Electrocardiograms results were compared to baseline of the open label extension study (day 84 minus baseline)

Time frame:
Baseline to day 84 of the open label extension portion of the study
Reported as:
Mean · milliseconds (ms)
Change From Baseline in Electrocardiograms (ECGs)
milliseconds (ms)PP405 0.05% Topical Gel (Open Label Extension Period)
PR Interval, Aggregate-1.3 ± 10.13
QRS Duration, Aggregate0.2 ± 5.48
QT Interval, Aggregate-5.5 ± 20.96
QTcB Interval, Aggregate-2.7 ± 23.02
QTcF Interval, Aggregate-3.6 ± 16.15
RR Interval, Aggregate-17.3 ± 151.89
PrimaryAbnormal Laboratory Values

Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)

Time frame:
Day 28 post baseline in the randomized portion of the study
Reported as:
Count of participants · Participants
Abnormal Laboratory Values
ParticipantsPP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Albumin (g/L) — Low00
Albumin (g/L) — Normal5125
Albumin (g/L) — High01
Alkaline Phosphatase (IU/L) — Low00
Alkaline Phosphatase (IU/L) — Normal5124
Alkaline Phosphatase (IU/L) — High02
Alanine Aminotransferase (IU/L) — Low00
Alanine Aminotransferase (IU/L) — Normal4122
Alanine Aminotransferase (IU/L) — High103
Aspartate Aminotransferase (IU/L) — Low00
Aspartate Aminotransferase (IU/L) — Normal4525
Aspartate Aminotransferase (IU/L) — High60
Bicarbonate (mmol/L) — Low2611
Bicarbonate (mmol/L) — Normal2515
Bicarbonate (mmol/L) — High00
Direct Bilirubin (umol/L) — Low00
Direct Bilirubin (umol/L) — Normal5025
Direct Bilirubin (umol/L) — High10
Bilirubin (umol/L) — Low00
Bilirubin (umol/L) — Normal4925
Bilirubin (umol/L) — High20
Calcium (mmol/L) — Low00
Calcium (mmol/L) — Normal4822
Calcium (mmol/L) — High34
Chloride (mmol/L) — Low10
Chloride (mmol/L) — Normal5026
Chloride (mmol/L) — High00
Cortisol (nmol/L) — Low00
Cortisol (nmol/L) — Normal4925
Cortisol (nmol/L) — High21
Creatinine (umol/L) — Low12
Creatinine (umol/L) — Normal4724
Creatinine (umol/L) — High30
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Low00
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Normal5126
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — High00
Gamma Glutamyl Transferase (IU/L) — Low00
Gamma Glutamyl Transferase (IU/L) — Normal4726
Gamma Glutamyl Transferase (IU/L) — High40
Glucose (mmol/L) — Low00
Glucose (mmol/L) — Normal4925
Glucose (mmol/L) — High21
Prothrombin Intl. Normalized Ratio — Low00
Prothrombin Intl. Normalized Ratio — Normal4519
Prothrombin Intl. Normalized Ratio — High47
Potassium (mmol/L) — Low10
Potassium (mmol/L) — Normal4926
Potassium (mmol/L) — High10
Lactate Dehydrogenase (IU/L) — Low74
Lactate Dehydrogenase (IU/L) — Normal4222
Lactate Dehydrogenase (IU/L) — High20
Phosphate (mmol/L) — Low31
Phosphate (mmol/L) — Normal4623
Phosphate (mmol/L) — High21
Protein (g/L) — Low40
Protein (g/L) — Normal4726
Protein (g/L) — High00
Sodium (mmol/L) — Low00
Sodium (mmol/L) — Normal5125
Sodium (mmol/L) — High01
Urate (umol/L) — Low00
Urate (umol/L) — Normal4323
Urate (umol/L) — High83
Urea Nitrogen (mmol/L) — Low32
Urea Nitrogen (mmol/L) — Normal4624
Urea Nitrogen (mmol/L) — High20
Basophils (10^9/L) — Low00
Basophils (10^9/L) — Normal5126
Basophils (10^9/L) — High00
Basophils/Leukocytes (%) — Low00
Basophils/Leukocytes (%) — Normal4824
Basophils/Leukocytes (%) — High32
Eosinophils (10^9/L) — Low00
Eosinophils (10^9/L) — Normal5126
Eosinophils (10^9/L) — High00
Eosinophils/Leukocytes (%) — Low00
Eosinophils/Leukocytes (%) — Normal5124
Eosinophils/Leukocytes (%) — High02
Hematocrit (L/L) — Low00
Hematocrit (L/L) — Normal5025
Hematocrit (L/L) — High11
Hemoglobin (g/L) — Low40
Hemoglobin (g/L) — Normal4525
Hemoglobin (g/L) — High21
Lymphocytes (10^9/L) — Low71
Lymphocytes (10^9/L) — Normal4225
Lymphocytes (10^9/L) — High20
Lymphocytes/Leukocytes (%) — Low21
Lymphocytes/Leukocytes (%) — Normal4923
Lymphocytes/Leukocytes (%) — High02
Ery. Mean Corpuscular Hemoglobin (pg) — Low20
Ery. Mean Corpuscular Hemoglobin (pg) — Normal4525
Ery. Mean Corpuscular Hemoglobin (pg) — High41
Ery. Mean Corpuscular HGB Concentration (g/L) — Low3717
Ery. Mean Corpuscular HGB Concentration (g/L) — Normal149
Ery. Mean Corpuscular HGB Concentration (g/L) — High00
Ery. Mean Corpuscular Volume (fL) — Low00
Ery. Mean Corpuscular Volume (fL) — Normal2612
Ery. Mean Corpuscular Volume (fL) — High2514
Monocytes (10^9/L) — Low31
Monocytes (10^9/L) — Normal4825
Monocytes (10^9/L) — High00
Monocytes/Leukocytes (%) — Low20
Monocytes/Leukocytes (%) — Normal4926
Monocytes/Leukocytes (%) — High00
Neutrophils (10^9/L) — Low22
Neutrophils (10^9/L) — Normal4724
Neutrophils (10^9/L) — High20
Neutrophils/Leukocytes (%) — Low12
Neutrophils/Leukocytes (%) — Normal4823
Neutrophils/Leukocytes (%) — High21
Platelets (10^9/L) — Low20
Platelets (10^9/L) — Normal4324
Platelets (10^9/L) — High62
Erythrocytes (10^12/L) — Low40
Erythrocytes (10^12/L) — Normal4326
Erythrocytes (10^12/L) — High40
Leukocytes (10^9/L) — Low30
Leukocytes (10^9/L) — Normal4626
Leukocytes (10^9/L) — High20
PrimaryAbnormal Laboratory Values

Chemistry and hematology laboratory values were recorded as normal or abnormal (low or high)

Time frame:
Day 84 post baseline in the open label extension portion of the study
Reported as:
Count of participants · Participants
Abnormal Laboratory Values
ParticipantsPP405 0.05% Topical Gel (Open Label Extension Period)
Albumin (g/L) — Low0
Albumin (g/L) — Normal20
Albumin (g/L) — High0
Alkaline Phosphatase (IU/L) — Low0
Alkaline Phosphatase (IU/L) — Normal19
Alkaline Phosphatase (IU/L) — High1
Alanine Aminotransferase (IU/L) — Low0
Alanine Aminotransferase (IU/L) — Normal18
Alanine Aminotransferase (IU/L) — High2
Aspartate Aminotransferase (IU/L) — Low0
Aspartate Aminotransferase (IU/L) — Normal19
Aspartate Aminotransferase (IU/L) — High1
Bicarbonate (mmol/L) — Low14
Bicarbonate (mmol/L) — Normal6
Bicarbonate (mmol/L) — High0
Direct Bilirubin (umol/L) — Low0
Direct Bilirubin (umol/L) — Normal18
Direct Bilirubin (umol/L) — High2
Bilirubin (umol/L) — Low0
Bilirubin (umol/L) — Normal19
Bilirubin (umol/L) — High1
Calcium (mmol/L) — Low0
Calcium (mmol/L) — Normal20
Calcium (mmol/L) — High0
Chloride (mmol/L) — Low0
Chloride (mmol/L) — Normal19
Chloride (mmol/L) — High1
Cortisol (nmol/L) — Low0
Cortisol (nmol/L) — Normal20
Cortisol (nmol/L) — High0
Creatinine (umol/L) — Low0
Creatinine (umol/L) — Normal19
Creatinine (umol/L) — High1
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Low0
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — Normal20
Glomerular Filtration Rate, Estimated (mL/min/1.73 m2) — High0
Gamma Glutamyl Transferase (IU/L) — Low1
Gamma Glutamyl Transferase (IU/L) — Normal18
Gamma Glutamyl Transferase (IU/L) — High1
Glucose (mmol/L) — Low0
Glucose (mmol/L) — Normal18
Glucose (mmol/L) — High2
Prothrombin Intl. Normalized Ratio — Low0
Prothrombin Intl. Normalized Ratio — Normal16
Prothrombin Intl. Normalized Ratio — High4
Potassium (mmol/L) — Low0
Potassium (mmol/L) — Normal20
Potassium (mmol/L) — High0
Lactate Dehydrogenase (IU/L) — Low4
Lactate Dehydrogenase (IU/L) — Normal16
Lactate Dehydrogenase (IU/L) — High0
Phosphate (mmol/L) — Low0
Phosphate (mmol/L) — Normal20
Phosphate (mmol/L) — High0
Protein (g/L) — Low1
Protein (g/L) — Normal19
Protein (g/L) — High0
Sodium (mmol/L) — Low0
Sodium (mmol/L) — Normal20
Sodium (mmol/L) — High0
Urate (umol/L) — Low0
Urate (umol/L) — Normal19
Urate (umol/L) — High1
Urea Nitrogen (mmol/L) — Low2
Urea Nitrogen (mmol/L) — Normal17
Urea Nitrogen (mmol/L) — High1
Basophils (10^9/L) — Low0
Basophils (10^9/L) — Normal20
Basophils (10^9/L) — High0
Basophils/Leukocytes (%) — Low0
Basophils/Leukocytes (%) — Normal19
Basophils/Leukocytes (%) — High1
Eosinophils (10^9/L) — Low0
Eosinophils (10^9/L) — Normal20
Eosinophils (10^9/L) — High0
Eosinophils/Leukocytes (%) — Low0
Eosinophils/Leukocytes (%) — Normal20
Eosinophils/Leukocytes (%) — High0
Hematocrit (L/L) — Low0
Hematocrit (L/L) — Normal20
Hematocrit (L/L) — High0
Hemoglobin (g/L) — Low2
Hemoglobin (g/L) — Normal17
Hemoglobin (g/L) — High1
Lymphocytes (10^9/L) — Low2
Lymphocytes (10^9/L) — Normal18
Lymphocytes (10^9/L) — High0
Lymphocytes/Leukocytes (%) — Low1
Lymphocytes/Leukocytes (%) — Normal19
Lymphocytes/Leukocytes (%) — High0
Ery. Mean Corpuscular Hemoglobin (pg) — Low0
Ery. Mean Corpuscular Hemoglobin (pg) — Normal20
Ery. Mean Corpuscular Hemoglobin (pg) — High0
Ery. Mean Corpuscular HGB Concentration (g/L) — Low15
Ery. Mean Corpuscular HGB Concentration (g/L) — Normal5
Ery. Mean Corpuscular HGB Concentration (g/L) — High0
Ery. Mean Corpuscular Volume (fL) — Low0
Ery. Mean Corpuscular Volume (fL) — Normal11
Ery. Mean Corpuscular Volume (fL) — High9
Monocytes (10^9/L) — Low0
Monocytes (10^9/L) — Normal20
Monocytes (10^9/L) — High0
Monocytes/Leukocytes (%) — Low0
Monocytes/Leukocytes (%) — Normal20
Monocytes/Leukocytes (%) — High0
Neutrophils (10^9/L) — Low0
Neutrophils (10^9/L) — Normal20
Neutrophils (10^9/L) — High0
Neutrophils/Leukocytes (%) — Low1
Neutrophils/Leukocytes (%) — Normal18
Neutrophils/Leukocytes (%) — High1
Platelets (10^9/L) — Low0
Platelets (10^9/L) — Normal19
Platelets (10^9/L) — High1
Erythrocytes (10^12/L) — Low0
Erythrocytes (10^12/L) — Normal19
Erythrocytes (10^12/L) — High1
Leukocytes (10^9/L) — Low0
Leukocytes (10^9/L) — Normal20
Leukocytes (10^9/L) — High0
SecondaryPharmacokinetics of PP405

To assess the concentration of PP405 in plasma

Time frame:
Baseline to Day 28 of the randomized portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 14, and day 28
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics of PP405
nanograms per milliliter (ng/mL)PP405 0.05% Topical Gel (Randomized Controlled Trial Period)Vehicle Gel (Randomized Controlled Trial Period)
Day 10 (0 to 0)—
Day 140 (0 to 0)—
Day 280 (0 to 0)—
SecondaryPharmacokinetics of PP405

To assess the concentration of PP405 in plasma

Time frame:
Baseline to Day 84 of the open label extension portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 28, day 56, and day 84
Reported as:
Mean · nanograms per milliliter (ng/mL)
Pharmacokinetics of PP405
nanograms per milliliter (ng/mL)PP405 0.05% Topical Gel (Open Label Extension Period)
Day 10 (0 to 0)
Day 280 (0 to 0)
Day 560 (0 to 0)
Day 840 (0 to 0)

Adverse events

Collected over Day 1 through day 84 of the randomized controlled portion of the study, and day 1 through day 168 of the open label extension portion of the study. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PP405 0.05% Topical Gel (Randomized Controlled Trial)0/51 (0%)0/51 (0%)22/51 (43.1%)
Topical Vehicle Gel (Randomized Controlled Trial)0/27 (0%)1/27 (3.7%)10/27 (37%)
PP405 0.05% Topical Gel (Open Label Extension)0/20 (0%)0/20 (0%)8/20 (40%)
Most frequent serious events
Most frequent serious events
EventPP405 0.05% Topical Gel (Randomized Controlled Trial)Topical Vehicle Gel (Randomized Controlled Trial)PP405 0.05% Topical Gel (Open Label Extension)
Upper extremity fractureInjury, poisoning and procedural complications0/511/27—
Most frequent other events
Showing 10 of 33
Most frequent other events
EventPP405 0.05% Topical Gel (Randomized Controlled Trial)Topical Vehicle Gel (Randomized Controlled Trial)PP405 0.05% Topical Gel (Open Label Extension)
Application site erythemaGeneral disorders4/513/273/20
Application site pruritisGeneral disorders7/512/272/20
PruritisSkin and subcutaneous tissue disorders3/513/271/20
Application site exfoliationGeneral disorders0/511/272/20
Application site painGeneral disorders2/512/270/20
COVID-19Infections and infestations2/510/271/20
Alanine aminotransferase increasedInvestigations0/510/271/20
Ligament sprainInjury, poisoning and procedural complications0/510/271/20
Fungal infectionInfections and infestations0/510/271/20
Viral upper respiratory tract infectionInfections and infestations0/510/271/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Mean39.0 ± 8.0838.4 ± 9.3838.8 ± 8.50
Sex: Female, Male
Sex: Female, Male(Participants)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Female6410
Male452368
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Hispanic or Latino14519
Not Hispanic or Latino372259
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
American Indian or Alaska Native000
Asian718
Native Hawaiian or Other Pacific Islander000
Black or African American8311
White352156
More than one race112
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
United States512778
Height
Height(Centimeters)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Mean174.09 ± 8.989176.13 ± 8.850174.80 ± 8.936
Weight
Weight(kilograms)PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Mean88.71 ± 18.22187.05 ± 84.3788.14 ± 17.934
Body mass index
Body mass index(kilograms / (meters^2))PP405 0.05% Topical GelTopical Vehicle Gel, Then PP405 0.05% Topical GelTotal
Mean29.20 ± 5.18228.03 ± 5.28628.80 ± 5.214
08

Study locations

8 sites
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Clinical Trials Research Institute
    Thousand Oaks, California 91320, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • DermResearch
    Austin, Texas 78759, United States
  • Stride Clinical Research LLC
    Sugar Land, Texas 77479, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jul 2025, 13 months.

Results were first posted in Sep 2026, 1 year 2 months after primary completion.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 13 months is close to that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2024
First posted
May 1, 2024
StartActual
Jun 5, 2024
Primary completionActual
Jul 16, 2025
CompletionActual
Oct 1, 2025
Results first posted
Sep 22, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 21, 2026
Secondary outcomes
2 time frame changed, 2 description edited
What changed in the outcomes
  • Time framePharmacokinetics of PP405Baseline to Day 28 of the randomized portion of the study → Baseline to Day 28 of the randomized portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 14, and day 28
  • Time framePharmacokinetics of PP405#2Baseline to Day 84 of the open label extension portion of the study → Baseline to Day 84 of the open label extension portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 28, day 56, and day 84
  • DescriptionPharmacokinetics of PP405: how it is measured was reworded
  • DescriptionPharmacokinetics of PP405#2: how it is measured was reworded
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Posted results revised
    Secondary outcomes 2 time frame changed, 2 description edited
    What changed in the outcomes
    • Time framePharmacokinetics of PP405Baseline to Day 28 of the randomized portion of the study → Baseline to Day 28 of the randomized portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 14, and day 28
    • Time framePharmacokinetics of PP405#2Baseline to Day 84 of the open label extension portion of the study → Baseline to Day 84 of the open label extension portion of the study, assessed at 2 hours (±10 minutes) post-dose on day 1, day 28, day 56, and day 84
    • DescriptionPharmacokinetics of PP405: how it is measured was reworded
    • DescriptionPharmacokinetics of PP405#2: how it is measured was reworded
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06393452
Lead sponsor
Pelage Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 1, 2024
Start date
Jun 5, 2024
Primary completion
Jul 16, 2025
Completion
Oct 1, 2025
Results posted
Sep 22, 2026
Last update
Oct 21, 2026

Study contacts

Christina Weng
study chair · Pelage Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JXL-069

Start the discussion